NEW YORK (GenomeWeb) – The US District Court for the Middle District of North Carolina has denied a motion brought by GlaxoSmithKline that sought to dismiss a patent infringement suit Genetic Technologies had filed against the drug giant two year ago.
"DxS is seeking to avoid its exclusive obligation with Roche because it no longer finds it advantageous to benefit from the Roche distribution network," but a termination of the agreement would cause "irreparable" harm, Roche stated in a recently filed complaint.
The suit revolves around patents owned by UNeMed, the technology-transfer organization for the UN Medical Center, and exclusively licensed to Abbot Laboratories, though Abbott is not listed as a co-plaintiff on the complaint.
The study, begun last year, will take longer than the June 2009 timeframe projected late last year. It calls for the NIH to analyze the ability of the Biosafety Level 4 lab to contain 13 toxins to be studied there, and ensure it can run safely.